Read the Beforeitsnews.com story here. Advertise at Before It's News here.
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views
Now:
Last hour:
Last 24 hours:
Total:

Recce Pharmaceuticals reveals positive safety data from phase I clinical trial of RECCE 327

% of readers think this story is Fact. Add your two cents.


Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has revealed further positive data from its phase I intravenous (IV) clinical trial of RECCE® 327 (R327), demonstrating safety and tolerability, among seven healthy male subjects in Cohort Two.

Based upon these clinical data readouts, an independent safety committee has approved a tenfold increase on the initial dosing of Cohort one (50mg) or threefold increase (from 150mg to 500mg) among 7-10 healthy subjects (Cohort Three).

Subjects are expected to be recruited this week and dosed immediately thereafter at Adelaide’s CMAX clinical trial facility.

“Successfully cleared two dosing levels”

R327 is one of the first new classes of antibiotics in over 30 years with a universal mechanism of action that allows its compounds to continuously kill bacteria and multi-drug resistant superbugs.

Recce Pharmaceuticals chief executive officer James Graham said: “We are pleased to see R327 (150mg) successfully tolerated as an intravenous infusion in Cohort Two subjects.

“Having successfully cleared two dosing levels (50mg and 150mg) we look forward to embarking upon this next significant milestone.”

Safety and tolerability demonstrated

R327 was shown to be safe and well-tolerated at the 150mg dose with no clinically significant changes in vital signs, clinical, adverse events, or laboratory parameters associated with R327.

The phase I trial is an ascending dose, randomized, placebo-controlled, parallel, double-blind, single-dose study being conducted at Adelaide’s CMAX clinical trial facility.

The study is evaluating the safety and pharmacokinetics of R327 in 7-10 healthy subjects per dose, across eight sequential dosing cohorts of 50-16,000mg.

The study is on track to have all phase I dosing complete by Q2 2022.

Story by ProactiveInvestors



Source: https://www.proactiveinvestors.com/companies/news/971396/recce-pharmaceuticals-reveals-positive-safety-data-from-phase-i-clinical-trial-of-recce-327-971396.html


Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world.

Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.

"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.

Please Help Support BeforeitsNews by trying our Natural Health Products below!


Order by Phone at 888-809-8385 or online at https://mitocopper.com M - F 9am to 5pm EST

Order by Phone at 866-388-7003 or online at https://www.herbanomic.com M - F 9am to 5pm EST

Order by Phone at 866-388-7003 or online at https://www.herbanomics.com M - F 9am to 5pm EST


Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!

HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation

Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.

MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser!  Cleans out toxic buildup with oxygen! 
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover -  Reduces Smart Meter radiation by 96%!  (See Video)

Report abuse

    Comments

    Your Comments
    Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

    MOST RECENT
    Load more ...

    SignUp

    Login

    Newsletter

    Email this story
    Email this story

    If you really want to ban this commenter, please write down the reason:

    If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.